Bristol-Myers Squibb remains a contrarian dividend Buy, despite the overbought technical indicators and growth headwinds.
The S&P 500 (SP500) is closing the year in a position of strength, extending its advance to fresh record territory as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback